nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—HBA2—gall bladder—Crohn's disease	0.0371	0.121	CbGeAlD
Mefloquine—HBA1—mouth—Crohn's disease	0.036	0.117	CbGeAlD
Mefloquine—HBA2—mouth—Crohn's disease	0.033	0.107	CbGeAlD
Mefloquine—HBA1—skin of body—Crohn's disease	0.0199	0.0647	CbGeAlD
Mefloquine—HBA2—epithelium—Crohn's disease	0.0192	0.0625	CbGeAlD
Mefloquine—HBA2—smooth muscle tissue—Crohn's disease	0.0185	0.0602	CbGeAlD
Mefloquine—HBA2—skin of body—Crohn's disease	0.0183	0.0594	CbGeAlD
Mefloquine—HBA1—lymphoid tissue—Crohn's disease	0.0161	0.0524	CbGeAlD
Mefloquine—HBA1—digestive system—Crohn's disease	0.0159	0.0518	CbGeAlD
Mefloquine—Schizophrenia—Prednisone—Crohn's disease	0.0152	0.0405	CcSEcCtD
Mefloquine—HBA2—lymphoid tissue—Crohn's disease	0.0148	0.0481	CbGeAlD
Mefloquine—HBA2—digestive system—Crohn's disease	0.0146	0.0475	CbGeAlD
Mefloquine—Breast feeding—Mesalazine—Crohn's disease	0.0111	0.0296	CcSEcCtD
Mefloquine—Haematocrit decreased—Mesalazine—Crohn's disease	0.0104	0.0278	CcSEcCtD
Mefloquine—HBA1—lymph node—Crohn's disease	0.00909	0.0296	CbGeAlD
Mefloquine—HBA2—lymph node—Crohn's disease	0.00835	0.0272	CbGeAlD
Mefloquine—ADORA2A—lymphoid tissue—Crohn's disease	0.0077	0.0251	CbGeAlD
Mefloquine—Hepatocellular injury—Mercaptopurine—Crohn's disease	0.00716	0.0191	CcSEcCtD
Mefloquine—Foetor hepaticus—Mesalazine—Crohn's disease	0.00685	0.0183	CcSEcCtD
Mefloquine—Liver disorder—Mesalazine—Crohn's disease	0.0057	0.0152	CcSEcCtD
Mefloquine—Epilepsy—Prednisone—Crohn's disease	0.00541	0.0144	CcSEcCtD
Mefloquine—Blister—Mesalazine—Crohn's disease	0.00539	0.0144	CcSEcCtD
Mefloquine—Hepatocellular injury—Azathioprine—Crohn's disease	0.00427	0.0114	CcSEcCtD
Mefloquine—Leukocytosis—Mesalazine—Crohn's disease	0.00414	0.011	CcSEcCtD
Mefloquine—BCHE—smooth muscle tissue—Crohn's disease	0.00406	0.0132	CbGeAlD
Mefloquine—BCHE—skin of body—Crohn's disease	0.00401	0.013	CbGeAlD
Mefloquine—Aplastic anaemia—Azathioprine—Crohn's disease	0.00401	0.0107	CcSEcCtD
Mefloquine—Hepatocellular injury—Mesalazine—Crohn's disease	0.00389	0.0104	CcSEcCtD
Mefloquine—Abnormal dreams—Mesalazine—Crohn's disease	0.00384	0.0102	CcSEcCtD
Mefloquine—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.00379	0.0101	CcSEcCtD
Mefloquine—Influenza like illness—Mesalazine—Crohn's disease	0.00378	0.0101	CcSEcCtD
Mefloquine—ADORA1—lymph node—Crohn's disease	0.00375	0.0122	CbGeAlD
Mefloquine—ACHE—lymph node—Crohn's disease	0.00373	0.0121	CbGeAlD
Mefloquine—BCHE—mammalian vulva—Crohn's disease	0.00366	0.0119	CbGeAlD
Mefloquine—Aplastic anaemia—Mesalazine—Crohn's disease	0.00365	0.00973	CcSEcCtD
Mefloquine—Neuropathy—Mesalazine—Crohn's disease	0.00365	0.00973	CcSEcCtD
Mefloquine—Coma—Mesalazine—Crohn's disease	0.00355	0.00947	CcSEcCtD
Mefloquine—Hepatic failure—Azathioprine—Crohn's disease	0.00345	0.00919	CcSEcCtD
Mefloquine—BCHE—digestive system—Crohn's disease	0.00321	0.0104	CbGeAlD
Mefloquine—Alopecia—Mercaptopurine—Crohn's disease	0.00318	0.00847	CcSEcCtD
Mefloquine—Deafness—Mesalazine—Crohn's disease	0.00315	0.00841	CcSEcCtD
Mefloquine—Hepatic failure—Mesalazine—Crohn's disease	0.00314	0.00837	CcSEcCtD
Mefloquine—Malnutrition—Mercaptopurine—Crohn's disease	0.00313	0.00834	CcSEcCtD
Mefloquine—Dermatitis bullous—Mesalazine—Crohn's disease	0.00295	0.00787	CcSEcCtD
Mefloquine—Suicidal ideation—Prednisone—Crohn's disease	0.00293	0.00782	CcSEcCtD
Mefloquine—Leukopenia—Mercaptopurine—Crohn's disease	0.0028	0.00747	CcSEcCtD
Mefloquine—Affect lability—Mesalazine—Crohn's disease	0.00278	0.0074	CcSEcCtD
Mefloquine—Neuritis—Prednisone—Crohn's disease	0.00275	0.00734	CcSEcCtD
Mefloquine—Mood swings—Mesalazine—Crohn's disease	0.00267	0.00712	CcSEcCtD
Mefloquine—Arthralgia—Mercaptopurine—Crohn's disease	0.00267	0.0071	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00265	0.00705	CcSEcCtD
Mefloquine—Memory impairment—Prednisone—Crohn's disease	0.00262	0.00698	CcSEcCtD
Mefloquine—Oedema—Mercaptopurine—Crohn's disease	0.00256	0.00681	CcSEcCtD
Mefloquine—CYP19A1—lymph node—Crohn's disease	0.00254	0.00828	CbGeAlD
Mefloquine—Cramp muscle—Mesalazine—Crohn's disease	0.00254	0.00677	CcSEcCtD
Mefloquine—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.0025	0.00667	CcSEcCtD
Mefloquine—Skin disorder—Mercaptopurine—Crohn's disease	0.00248	0.00661	CcSEcCtD
Mefloquine—Pneumonia—Azathioprine—Crohn's disease	0.0024	0.0064	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00237	0.00631	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00233	0.0062	CcSEcCtD
Mefloquine—Hepatobiliary disease—Azathioprine—Crohn's disease	0.00226	0.00602	CcSEcCtD
Mefloquine—Agranulocytosis—Azathioprine—Crohn's disease	0.00223	0.00594	CcSEcCtD
Mefloquine—Decreased appetite—Mercaptopurine—Crohn's disease	0.00222	0.00592	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00221	0.00588	CcSEcCtD
Mefloquine—Leukocytosis—Prednisone—Crohn's disease	0.00219	0.00583	CcSEcCtD
Mefloquine—Pneumonia—Mesalazine—Crohn's disease	0.00219	0.00583	CcSEcCtD
Mefloquine—Cataract—Prednisone—Crohn's disease	0.00216	0.00576	CcSEcCtD
Mefloquine—CYP3A4—digestive system—Crohn's disease	0.00216	0.00703	CbGeAlD
Mefloquine—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.00216	0.00575	CcSEcCtD
Mefloquine—Renal failure—Mesalazine—Crohn's disease	0.00214	0.0057	CcSEcCtD
Mefloquine—Neuropathy peripheral—Mesalazine—Crohn's disease	0.00213	0.00568	CcSEcCtD
Mefloquine—CYP2D6—digestive system—Crohn's disease	0.00213	0.00691	CbGeAlD
Mefloquine—Sweating—Mesalazine—Crohn's disease	0.00208	0.00556	CcSEcCtD
Mefloquine—Hepatobiliary disease—Mesalazine—Crohn's disease	0.00206	0.00548	CcSEcCtD
Mefloquine—Agranulocytosis—Mesalazine—Crohn's disease	0.00203	0.00541	CcSEcCtD
Mefloquine—Erythema multiforme—Azathioprine—Crohn's disease	0.00203	0.0054	CcSEcCtD
Mefloquine—Body temperature increased—Mercaptopurine—Crohn's disease	0.00202	0.00538	CcSEcCtD
Mefloquine—ABCB1—epithelium—Crohn's disease	0.00201	0.00654	CbGeAlD
Mefloquine—Mediastinal disorder—Azathioprine—Crohn's disease	0.00193	0.00515	CcSEcCtD
Mefloquine—Neuropathy—Prednisone—Crohn's disease	0.00193	0.00515	CcSEcCtD
Mefloquine—Chills—Azathioprine—Crohn's disease	0.00192	0.00512	CcSEcCtD
Mefloquine—Connective tissue disorder—Mesalazine—Crohn's disease	0.00192	0.00511	CcSEcCtD
Mefloquine—Alopecia—Azathioprine—Crohn's disease	0.00189	0.00505	CcSEcCtD
Mefloquine—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00188	0.00502	CcSEcCtD
Mefloquine—Erythema multiforme—Mesalazine—Crohn's disease	0.00185	0.00492	CcSEcCtD
Mefloquine—BCHE—lymph node—Crohn's disease	0.00183	0.00596	CbGeAlD
Mefloquine—Eye disorder—Mesalazine—Crohn's disease	0.00182	0.00486	CcSEcCtD
Mefloquine—Tinnitus—Mesalazine—Crohn's disease	0.00182	0.00485	CcSEcCtD
Mefloquine—Cardiac disorder—Mesalazine—Crohn's disease	0.00181	0.00483	CcSEcCtD
Mefloquine—Angiopathy—Mesalazine—Crohn's disease	0.00177	0.00472	CcSEcCtD
Mefloquine—Mediastinal disorder—Mesalazine—Crohn's disease	0.00176	0.00469	CcSEcCtD
Mefloquine—Chills—Mesalazine—Crohn's disease	0.00175	0.00467	CcSEcCtD
Mefloquine—Diarrhoea—Mercaptopurine—Crohn's disease	0.00175	0.00466	CcSEcCtD
Mefloquine—ABCB1—mammalian vulva—Crohn's disease	0.00174	0.00567	CbGeAlD
Mefloquine—Ill-defined disorder—Azathioprine—Crohn's disease	0.00173	0.00461	CcSEcCtD
Mefloquine—Alopecia—Mesalazine—Crohn's disease	0.00172	0.0046	CcSEcCtD
Mefloquine—Mental disorder—Mesalazine—Crohn's disease	0.00171	0.00456	CcSEcCtD
Mefloquine—Erythema—Mesalazine—Crohn's disease	0.0017	0.00453	CcSEcCtD
Mefloquine—Malaise—Azathioprine—Crohn's disease	0.00168	0.00448	CcSEcCtD
Mefloquine—Leukopenia—Azathioprine—Crohn's disease	0.00167	0.00445	CcSEcCtD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00164	0.00516	CbGpPWpGaD
Mefloquine—Muscle spasms—Mesalazine—Crohn's disease	0.00163	0.00435	CcSEcCtD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00163	0.00512	CbGpPWpGaD
Mefloquine—Vomiting—Mercaptopurine—Crohn's disease	0.00162	0.00433	CcSEcCtD
Mefloquine—ADORA1—GPCR ligand binding—ACKR2—Crohn's disease	0.00161	0.00509	CbGpPWpGaD
Mefloquine—Rash—Mercaptopurine—Crohn's disease	0.00161	0.00429	CcSEcCtD
Mefloquine—Dermatitis—Mercaptopurine—Crohn's disease	0.00161	0.00429	CcSEcCtD
Mefloquine—Vision blurred—Mesalazine—Crohn's disease	0.0016	0.00427	CcSEcCtD
Mefloquine—Tremor—Mesalazine—Crohn's disease	0.00159	0.00424	CcSEcCtD
Mefloquine—Myalgia—Azathioprine—Crohn's disease	0.00159	0.00423	CcSEcCtD
Mefloquine—Arthralgia—Azathioprine—Crohn's disease	0.00159	0.00423	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00158	0.0042	CcSEcCtD
Mefloquine—Ill-defined disorder—Mesalazine—Crohn's disease	0.00158	0.0042	CcSEcCtD
Mefloquine—Discomfort—Azathioprine—Crohn's disease	0.00157	0.00418	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—MST1—Crohn's disease	0.00156	0.00493	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—PLA2G4F—Crohn's disease	0.00156	0.00491	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00155	0.00489	CbGpPWpGaD
Mefloquine—ABCB1—lymphoid tissue—Crohn's disease	0.00155	0.00504	CbGeAlD
Mefloquine—Malaise—Mesalazine—Crohn's disease	0.00153	0.00408	CcSEcCtD
Mefloquine—ADORA1—GPCR ligand binding—MLN—Crohn's disease	0.00153	0.00482	CbGpPWpGaD
Mefloquine—ABCB1—digestive system—Crohn's disease	0.00153	0.00497	CbGeAlD
Mefloquine—Vertigo—Mesalazine—Crohn's disease	0.00153	0.00407	CcSEcCtD
Mefloquine—Syncope—Mesalazine—Crohn's disease	0.00152	0.00406	CcSEcCtD
Mefloquine—Leukopenia—Mesalazine—Crohn's disease	0.00152	0.00405	CcSEcCtD
Mefloquine—Nausea—Mercaptopurine—Crohn's disease	0.00152	0.00404	CcSEcCtD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00151	0.00476	CbGpPWpGaD
Mefloquine—Palpitations—Mesalazine—Crohn's disease	0.0015	0.004	CcSEcCtD
Mefloquine—Loss of consciousness—Mesalazine—Crohn's disease	0.00149	0.00398	CcSEcCtD
Mefloquine—Thrombocytopenia—Azathioprine—Crohn's disease	0.00149	0.00397	CcSEcCtD
Mefloquine—Skin disorder—Azathioprine—Crohn's disease	0.00148	0.00394	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—ZMIZ1—Crohn's disease	0.00148	0.00465	CbGpPWpGaD
Mefloquine—Affect lability—Prednisone—Crohn's disease	0.00147	0.00392	CcSEcCtD
Mefloquine—Hypertension—Mesalazine—Crohn's disease	0.00147	0.00391	CcSEcCtD
Mefloquine—Psychotic disorder—Prednisone—Crohn's disease	0.00146	0.00389	CcSEcCtD
Mefloquine—Arthralgia—Mesalazine—Crohn's disease	0.00145	0.00386	CcSEcCtD
Mefloquine—Myalgia—Mesalazine—Crohn's disease	0.00145	0.00386	CcSEcCtD
Mefloquine—Chest pain—Mesalazine—Crohn's disease	0.00145	0.00386	CcSEcCtD
Mefloquine—Anxiety—Mesalazine—Crohn's disease	0.00144	0.00384	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.00144	0.00383	CcSEcCtD
Mefloquine—Discomfort—Mesalazine—Crohn's disease	0.00143	0.00381	CcSEcCtD
Mefloquine—Irritability—Prednisone—Crohn's disease	0.00142	0.0038	CcSEcCtD
Mefloquine—Hypotension—Azathioprine—Crohn's disease	0.00142	0.00379	CcSEcCtD
Mefloquine—HBA1—Selenium Micronutrient Network—IL6—Crohn's disease	0.00141	0.00446	CbGpPWpGaD
Mefloquine—Mood swings—Prednisone—Crohn's disease	0.00141	0.00377	CcSEcCtD
Mefloquine—Confusional state—Mesalazine—Crohn's disease	0.0014	0.00373	CcSEcCtD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00139	0.00439	CbGpPWpGaD
Mefloquine—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00139	0.0037	CcSEcCtD
Mefloquine—Oedema—Mesalazine—Crohn's disease	0.00139	0.0037	CcSEcCtD
Mefloquine—Anaphylactic shock—Mesalazine—Crohn's disease	0.00139	0.0037	CcSEcCtD
Mefloquine—ADORA2A—Monoamine Transport—IL1B—Crohn's disease	0.00137	0.0043	CbGpPWpGaD
Mefloquine—Shock—Mesalazine—Crohn's disease	0.00136	0.00364	CcSEcCtD
Mefloquine—HBA2—Metabolism—FADS1—Crohn's disease	0.00136	0.00429	CbGpPWpGaD
Mefloquine—Nervous system disorder—Mesalazine—Crohn's disease	0.00136	0.00362	CcSEcCtD
Mefloquine—Thrombocytopenia—Mesalazine—Crohn's disease	0.00136	0.00362	CcSEcCtD
Mefloquine—Tachycardia—Mesalazine—Crohn's disease	0.00135	0.00361	CcSEcCtD
Mefloquine—Skin disorder—Mesalazine—Crohn's disease	0.00135	0.00359	CcSEcCtD
Mefloquine—Hyperhidrosis—Mesalazine—Crohn's disease	0.00134	0.00357	CcSEcCtD
Mefloquine—HBA1—Metabolism—MTMR3—Crohn's disease	0.00132	0.00417	CbGpPWpGaD
Mefloquine—Muscular weakness—Prednisone—Crohn's disease	0.00132	0.00351	CcSEcCtD
Mefloquine—ADORA2A—G alpha (s) signalling events—PTGER4—Crohn's disease	0.00132	0.00415	CbGpPWpGaD
Mefloquine—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00131	0.0035	CcSEcCtD
Mefloquine—Hypotension—Mesalazine—Crohn's disease	0.0013	0.00345	CcSEcCtD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00129	0.00408	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—GPX4—Crohn's disease	0.00127	0.00402	CbGpPWpGaD
Mefloquine—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00126	0.00337	CcSEcCtD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00126	0.00396	CbGpPWpGaD
Mefloquine—Feeling abnormal—Azathioprine—Crohn's disease	0.00125	0.00334	CcSEcCtD
Mefloquine—Insomnia—Mesalazine—Crohn's disease	0.00125	0.00334	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—ACKR2—Crohn's disease	0.00125	0.00393	CbGpPWpGaD
Mefloquine—Paraesthesia—Mesalazine—Crohn's disease	0.00125	0.00332	CcSEcCtD
Mefloquine—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00125	0.00332	CcSEcCtD
Mefloquine—Dyspnoea—Mesalazine—Crohn's disease	0.00124	0.0033	CcSEcCtD
Mefloquine—Somnolence—Mesalazine—Crohn's disease	0.00123	0.00329	CcSEcCtD
Mefloquine—HBA2—Metabolism—GCKR—Crohn's disease	0.00123	0.00388	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—LRRK2—Crohn's disease	0.00123	0.00388	CbGpPWpGaD
Mefloquine—Dyspepsia—Mesalazine—Crohn's disease	0.00122	0.00325	CcSEcCtD
Mefloquine—Decreased appetite—Mesalazine—Crohn's disease	0.00121	0.00321	CcSEcCtD
Mefloquine—Body temperature increased—Azathioprine—Crohn's disease	0.0012	0.00321	CcSEcCtD
Mefloquine—Abdominal pain—Azathioprine—Crohn's disease	0.0012	0.00321	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.0012	0.00319	CcSEcCtD
Mefloquine—Fatigue—Mesalazine—Crohn's disease	0.0012	0.00319	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—MLN—Crohn's disease	0.00118	0.00372	CbGpPWpGaD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00117	0.00368	CbGpPWpGaD
Mefloquine—ADORA1—G alpha (i) signalling events—CCR6—Crohn's disease	0.00116	0.00366	CbGpPWpGaD
Mefloquine—Feeling abnormal—Mesalazine—Crohn's disease	0.00114	0.00305	CcSEcCtD
Mefloquine—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00113	0.00302	CcSEcCtD
Mefloquine—Neuropathy peripheral—Prednisone—Crohn's disease	0.00113	0.00301	CcSEcCtD
Mefloquine—Hypersensitivity—Azathioprine—Crohn's disease	0.00112	0.00299	CcSEcCtD
Mefloquine—Urticaria—Mesalazine—Crohn's disease	0.0011	0.00294	CcSEcCtD
Mefloquine—Body temperature increased—Mesalazine—Crohn's disease	0.0011	0.00292	CcSEcCtD
Mefloquine—Abdominal pain—Mesalazine—Crohn's disease	0.0011	0.00292	CcSEcCtD
Mefloquine—ACHE—Monoamine Transport—IL1B—Crohn's disease	0.00109	0.00344	CbGpPWpGaD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.00108	0.00339	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00108	0.00339	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—CCR9—Crohn's disease	0.00106	0.00334	CbGpPWpGaD
Mefloquine—Bradycardia—Prednisone—Crohn's disease	0.00105	0.0028	CcSEcCtD
Mefloquine—Diarrhoea—Azathioprine—Crohn's disease	0.00104	0.00278	CcSEcCtD
Mefloquine—HBA1—Metabolism—FADS1—Crohn's disease	0.00103	0.00325	CbGpPWpGaD
Mefloquine—CYP19A1—Metapathway biotransformation—GPX4—Crohn's disease	0.00103	0.00324	CbGpPWpGaD
Mefloquine—Hallucination—Prednisone—Crohn's disease	0.00103	0.00274	CcSEcCtD
Mefloquine—Hypersensitivity—Mesalazine—Crohn's disease	0.00102	0.00272	CcSEcCtD
Mefloquine—Connective tissue disorder—Prednisone—Crohn's disease	0.00101	0.0027	CcSEcCtD
Mefloquine—Dizziness—Azathioprine—Crohn's disease	0.00101	0.00268	CcSEcCtD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.001	0.00315	CbGpPWpGaD
Mefloquine—Asthenia—Mesalazine—Crohn's disease	0.000995	0.00265	CcSEcCtD
Mefloquine—ADORA2A—Monoamine Transport—TNF—Crohn's disease	0.000991	0.00312	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—GPR65—Crohn's disease	0.000986	0.00311	CbGpPWpGaD
Mefloquine—Pruritus—Mesalazine—Crohn's disease	0.000981	0.00261	CcSEcCtD
Mefloquine—Vomiting—Azathioprine—Crohn's disease	0.000968	0.00258	CcSEcCtD
Mefloquine—HBA1—Metabolism—GPX4—Crohn's disease	0.000966	0.00304	CbGpPWpGaD
Mefloquine—Eye disorder—Prednisone—Crohn's disease	0.000965	0.00257	CcSEcCtD
Mefloquine—Rash—Azathioprine—Crohn's disease	0.00096	0.00256	CcSEcCtD
Mefloquine—Dermatitis—Azathioprine—Crohn's disease	0.000959	0.00256	CcSEcCtD
Mefloquine—Flushing—Prednisone—Crohn's disease	0.000959	0.00255	CcSEcCtD
Mefloquine—Headache—Azathioprine—Crohn's disease	0.000954	0.00254	CcSEcCtD
Mefloquine—Diarrhoea—Mesalazine—Crohn's disease	0.000949	0.00253	CcSEcCtD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.000948	0.00299	CbGpPWpGaD
Mefloquine—Angiopathy—Prednisone—Crohn's disease	0.000937	0.0025	CcSEcCtD
Mefloquine—HBA1—Metabolism—GCKR—Crohn's disease	0.000933	0.00294	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000923	0.00291	CbGpPWpGaD
Mefloquine—Dizziness—Mesalazine—Crohn's disease	0.000917	0.00244	CcSEcCtD
Mefloquine—Alopecia—Prednisone—Crohn's disease	0.000913	0.00243	CcSEcCtD
Mefloquine—Mental disorder—Prednisone—Crohn's disease	0.000905	0.00241	CcSEcCtD
Mefloquine—Nausea—Azathioprine—Crohn's disease	0.000904	0.00241	CcSEcCtD
Mefloquine—Malnutrition—Prednisone—Crohn's disease	0.000899	0.0024	CcSEcCtD
Mefloquine—Erythema—Prednisone—Crohn's disease	0.000899	0.0024	CcSEcCtD
Mefloquine—Vomiting—Mesalazine—Crohn's disease	0.000882	0.00235	CcSEcCtD
Mefloquine—ACHE—Metabolism of proteins—SBSPON—Crohn's disease	0.000876	0.00276	CbGpPWpGaD
Mefloquine—Rash—Mesalazine—Crohn's disease	0.000874	0.00233	CcSEcCtD
Mefloquine—Dermatitis—Mesalazine—Crohn's disease	0.000874	0.00233	CcSEcCtD
Mefloquine—ABCB1—lymph node—Crohn's disease	0.000874	0.00284	CbGeAlD
Mefloquine—Headache—Mesalazine—Crohn's disease	0.000869	0.00232	CcSEcCtD
Mefloquine—ADORA1—GPCR downstream signaling—MLN—Crohn's disease	0.000865	0.00273	CbGpPWpGaD
Mefloquine—Vision blurred—Prednisone—Crohn's disease	0.000847	0.00226	CcSEcCtD
Mefloquine—Ill-defined disorder—Prednisone—Crohn's disease	0.000834	0.00222	CcSEcCtD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.000831	0.00262	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—ACKR2—Crohn's disease	0.000828	0.00261	CbGpPWpGaD
Mefloquine—Agitation—Prednisone—Crohn's disease	0.000826	0.0022	CcSEcCtD
Mefloquine—Nausea—Mesalazine—Crohn's disease	0.000824	0.0022	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—CCR9—Crohn's disease	0.000819	0.00258	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000812	0.00256	CbGpPWpGaD
Mefloquine—Malaise—Prednisone—Crohn's disease	0.000811	0.00216	CcSEcCtD
Mefloquine—Vertigo—Prednisone—Crohn's disease	0.000808	0.00215	CcSEcCtD
Mefloquine—Syncope—Prednisone—Crohn's disease	0.000806	0.00215	CcSEcCtD
Mefloquine—ACHE—Monoamine Transport—TNF—Crohn's disease	0.000791	0.00249	CbGpPWpGaD
Mefloquine—Loss of consciousness—Prednisone—Crohn's disease	0.00079	0.00211	CcSEcCtD
Mefloquine—ADORA1—Signaling by GPCR—MLN—Crohn's disease	0.000785	0.00247	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—SBSPON—Crohn's disease	0.000781	0.00246	CbGpPWpGaD
Mefloquine—Convulsion—Prednisone—Crohn's disease	0.000779	0.00208	CcSEcCtD
Mefloquine—Hypertension—Prednisone—Crohn's disease	0.000776	0.00207	CcSEcCtD
Mefloquine—Arthralgia—Prednisone—Crohn's disease	0.000765	0.00204	CcSEcCtD
Mefloquine—Myalgia—Prednisone—Crohn's disease	0.000765	0.00204	CcSEcCtD
Mefloquine—Anxiety—Prednisone—Crohn's disease	0.000763	0.00203	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—GPR65—Crohn's disease	0.000761	0.0024	CbGpPWpGaD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.00076	0.00203	CcSEcCtD
Mefloquine—Discomfort—Prednisone—Crohn's disease	0.000756	0.00202	CcSEcCtD
Mefloquine—ACHE—ATF-2 transcription factor network—IFNG—Crohn's disease	0.000749	0.00236	CbGpPWpGaD
Mefloquine—Oedema—Prednisone—Crohn's disease	0.000734	0.00196	CcSEcCtD
Mefloquine—Anaphylactic shock—Prednisone—Crohn's disease	0.000734	0.00196	CcSEcCtD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.000732	0.00231	CbGpPWpGaD
Mefloquine—Shock—Prednisone—Crohn's disease	0.000722	0.00192	CcSEcCtD
Mefloquine—Nervous system disorder—Prednisone—Crohn's disease	0.00072	0.00192	CcSEcCtD
Mefloquine—Tachycardia—Prednisone—Crohn's disease	0.000716	0.00191	CcSEcCtD
Mefloquine—Skin disorder—Prednisone—Crohn's disease	0.000713	0.0019	CcSEcCtD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000712	0.00225	CbGpPWpGaD
Mefloquine—Hyperhidrosis—Prednisone—Crohn's disease	0.000709	0.00189	CcSEcCtD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000703	0.00221	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—CCR6—Crohn's disease	0.000703	0.00221	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—CXCL8—Crohn's disease	0.000697	0.0022	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MST1—Crohn's disease	0.000681	0.00215	CbGpPWpGaD
Mefloquine—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000669	0.00178	CcSEcCtD
Mefloquine—ADORA2A—GPCR downstream signaling—MLN—Crohn's disease	0.000668	0.0021	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—TAB1—Crohn's disease	0.000665	0.0021	CbGpPWpGaD
Mefloquine—Insomnia—Prednisone—Crohn's disease	0.000664	0.00177	CcSEcCtD
Mefloquine—Paraesthesia—Prednisone—Crohn's disease	0.000659	0.00176	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—IL17A—Crohn's disease	0.000646	0.00204	CbGpPWpGaD
Mefloquine—Dyspepsia—Prednisone—Crohn's disease	0.000646	0.00172	CcSEcCtD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000646	0.00203	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—ACKR2—Crohn's disease	0.00064	0.00202	CbGpPWpGaD
Mefloquine—Decreased appetite—Prednisone—Crohn's disease	0.000638	0.0017	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	0.000633	0.002	CbGpPWpGaD
Mefloquine—Fatigue—Prednisone—Crohn's disease	0.000633	0.00169	CcSEcCtD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000627	0.00198	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000627	0.00198	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—PTGER4—Crohn's disease	0.000619	0.00195	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—MLN—Crohn's disease	0.000606	0.00191	CbGpPWpGaD
Mefloquine—Feeling abnormal—Prednisone—Crohn's disease	0.000605	0.00161	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—IL12B—Crohn's disease	0.000601	0.00189	CbGpPWpGaD
Mefloquine—Gastrointestinal pain—Prednisone—Crohn's disease	0.0006	0.0016	CcSEcCtD
Mefloquine—ADORA1—GPCR downstream signaling—CCR9—Crohn's disease	0.000599	0.00189	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000597	0.00188	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—RIPK2—Crohn's disease	0.000589	0.00186	CbGpPWpGaD
Mefloquine—Urticaria—Prednisone—Crohn's disease	0.000583	0.00155	CcSEcCtD
Mefloquine—Body temperature increased—Prednisone—Crohn's disease	0.00058	0.00155	CcSEcCtD
Mefloquine—Abdominal pain—Prednisone—Crohn's disease	0.00058	0.00155	CcSEcCtD
Mefloquine—ADORA1—GPCR downstream signaling—GPR65—Crohn's disease	0.000557	0.00176	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000549	0.00173	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CCR9—Crohn's disease	0.000544	0.00172	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CCR6—Crohn's disease	0.000542	0.00171	CbGpPWpGaD
Mefloquine—Hypersensitivity—Prednisone—Crohn's disease	0.000541	0.00144	CcSEcCtD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000533	0.00168	CbGpPWpGaD
Mefloquine—Asthenia—Prednisone—Crohn's disease	0.000526	0.0014	CcSEcCtD
Mefloquine—Pruritus—Prednisone—Crohn's disease	0.000519	0.00138	CcSEcCtD
Mefloquine—ADORA1—Signaling by GPCR—GPR65—Crohn's disease	0.000506	0.00159	CbGpPWpGaD
Mefloquine—Diarrhoea—Prednisone—Crohn's disease	0.000502	0.00134	CcSEcCtD
Mefloquine—ADORA1—Signaling Pathways—ACKR2—Crohn's disease	0.000489	0.00154	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—SMAD3—Crohn's disease	0.000488	0.00154	CbGpPWpGaD
Mefloquine—Dizziness—Prednisone—Crohn's disease	0.000485	0.00129	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—PTGER4—Crohn's disease	0.000478	0.00151	CbGpPWpGaD
Mefloquine—Vomiting—Prednisone—Crohn's disease	0.000467	0.00124	CcSEcCtD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000465	0.00147	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MLN—Crohn's disease	0.000464	0.00146	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—CCR9—Crohn's disease	0.000463	0.00146	CbGpPWpGaD
Mefloquine—Rash—Prednisone—Crohn's disease	0.000463	0.00123	CcSEcCtD
Mefloquine—Dermatitis—Prednisone—Crohn's disease	0.000462	0.00123	CcSEcCtD
Mefloquine—Headache—Prednisone—Crohn's disease	0.00046	0.00123	CcSEcCtD
Mefloquine—CYP2D6—Metapathway biotransformation—GPX4—Crohn's disease	0.000459	0.00145	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IL10—Crohn's disease	0.000439	0.00138	CbGpPWpGaD
Mefloquine—Nausea—Prednisone—Crohn's disease	0.000436	0.00116	CcSEcCtD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000436	0.00137	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—GPR65—Crohn's disease	0.00043	0.00136	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000428	0.00135	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TAGAP—Crohn's disease	0.000424	0.00134	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CCR9—Crohn's disease	0.00042	0.00132	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000415	0.00131	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000401	0.00126	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—CCR6—Crohn's disease	0.000397	0.00125	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—ALB—Crohn's disease	0.000392	0.00123	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IL2RA—Crohn's disease	0.000391	0.00123	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—IL6—Crohn's disease	0.000391	0.00123	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—GPR65—Crohn's disease	0.000391	0.00123	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000389	0.00123	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ACKR2—Crohn's disease	0.000378	0.00119	CbGpPWpGaD
Mefloquine—ADORA1—G alpha (i) signalling events—CXCL8—Crohn's disease	0.000374	0.00118	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RSPO3—Crohn's disease	0.000371	0.00117	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—TYK2—Crohn's disease	0.000368	0.00116	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CCR6—Crohn's disease	0.000361	0.00114	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MLN—Crohn's disease	0.000358	0.00113	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SEL1L—Crohn's disease	0.000352	0.00111	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—JAK2—Crohn's disease	0.000352	0.00111	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—PTGER4—Crohn's disease	0.00035	0.0011	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—PTGS2—Crohn's disease	0.000343	0.00108	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TAGAP—Crohn's disease	0.000328	0.00103	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCR9—Crohn's disease	0.000322	0.00101	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PTGER4—Crohn's disease	0.000317	0.001	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PLA2G4F—Crohn's disease	0.000313	0.000986	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—CCR6—Crohn's disease	0.000307	0.000966	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	0.0003	0.000946	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—GPR65—Crohn's disease	0.000299	0.000942	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—IL3—Crohn's disease	0.000298	0.000938	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000297	0.000937	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—ALB—Crohn's disease	0.000297	0.000936	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000288	0.000908	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PLA2G4F—Crohn's disease	0.000288	0.000906	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RSPO3—Crohn's disease	0.000286	0.000902	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—TYK2—Crohn's disease	0.000283	0.000893	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	0.000281	0.000885	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PLA2G4F—Crohn's disease	0.000279	0.00088	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CCR6—Crohn's disease	0.000278	0.000877	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	0.000276	0.000869	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SEL1L—Crohn's disease	0.000271	0.000856	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL3—Crohn's disease	0.00027	0.000852	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—JAK2—Crohn's disease	0.00027	0.000852	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PTGER4—Crohn's disease	0.00027	0.000851	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—MTMR3—Crohn's disease	0.000266	0.000839	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—RASGRP1—Crohn's disease	0.000262	0.000824	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—PTGS2—Crohn's disease	0.00026	0.000819	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IFNG—Crohn's disease	0.000258	0.000814	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—Crohn's disease	0.000258	0.000813	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCR9—Crohn's disease	0.000248	0.000782	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000247	0.000779	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000247	0.000779	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PTGER4—Crohn's disease	0.000245	0.000772	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—MTMR3—Crohn's disease	0.000245	0.000771	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—CXCL8—Crohn's disease	0.00024	0.000757	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—IL6—Crohn's disease	0.000238	0.00075	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—MTMR3—Crohn's disease	0.000237	0.000748	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—GPR65—Crohn's disease	0.000231	0.000727	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IL1B—Crohn's disease	0.00023	0.000726	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—IL3—Crohn's disease	0.00023	0.000725	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.00023	0.000724	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—CXCL8—Crohn's disease	0.000226	0.000714	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000222	0.000701	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCR6—Crohn's disease	0.000213	0.000671	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL3—Crohn's disease	0.000209	0.000658	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—IL2RA—Crohn's disease	0.000209	0.000657	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—FADS1—Crohn's disease	0.000207	0.000653	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—RASGRP1—Crohn's disease	0.000202	0.000636	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—STAT3—Crohn's disease	0.000198	0.000625	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GPX4—Crohn's disease	0.000194	0.000612	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RBX1—Crohn's disease	0.000193	0.000607	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—FADS1—Crohn's disease	0.00019	0.0006	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	0.000189	0.000597	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL2RA—Crohn's disease	0.000189	0.000597	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTGER4—Crohn's disease	0.000188	0.000591	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GCKR—Crohn's disease	0.000187	0.000591	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—FADS1—Crohn's disease	0.000185	0.000583	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—IL6—Crohn's disease	0.000184	0.000579	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	0.00018	0.000568	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GPX4—Crohn's disease	0.000178	0.000562	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CXCL8—Crohn's disease	0.000175	0.000551	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000174	0.000549	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GPX4—Crohn's disease	0.000173	0.000546	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GCKR—Crohn's disease	0.000172	0.000543	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—UBE2D1—Crohn's disease	0.000169	0.000532	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GCKR—Crohn's disease	0.000167	0.000527	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—TNF—Crohn's disease	0.000167	0.000527	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCR6—Crohn's disease	0.000164	0.000518	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RIPK2—Crohn's disease	0.000164	0.000516	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—IL2RA—Crohn's disease	0.000161	0.000508	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL3—Crohn's disease	0.00016	0.000503	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RASGRP1—Crohn's disease	0.000154	0.000487	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000154	0.000485	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RBX1—Crohn's disease	0.000149	0.000469	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL2RA—Crohn's disease	0.000146	0.000461	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTGER4—Crohn's disease	0.000145	0.000456	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—JAK2—Crohn's disease	0.00014	0.000442	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SOCS1—Crohn's disease	0.00014	0.000441	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—IL6—Crohn's disease	0.000139	0.000437	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PLA2G4F—Crohn's disease	0.000136	0.000429	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	0.000134	0.000422	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—TYK2—Crohn's disease	0.000133	0.000421	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—UBE2D1—Crohn's disease	0.00013	0.000411	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	0.000128	0.000405	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—CXCL8—Crohn's disease	0.000128	0.000403	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—JAK2—Crohn's disease	0.000127	0.000401	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RIPK2—Crohn's disease	0.000126	0.000399	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL3—Crohn's disease	0.000123	0.000389	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	0.000123	0.000388	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	0.000122	0.000385	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SMAD3—Crohn's disease	0.000121	0.000381	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	0.00012	0.000377	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RASGRP1—Crohn's disease	0.000119	0.000376	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	0.000117	0.000369	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CXCL8—Crohn's disease	0.000116	0.000366	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—MTMR3—Crohn's disease	0.000116	0.000365	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL2RA—Crohn's disease	0.000112	0.000353	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—MTMR3—Crohn's disease	0.000109	0.000344	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—JAK2—Crohn's disease	0.000108	0.000341	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SOCS1—Crohn's disease	0.000108	0.000341	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	0.000108	0.000339	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	0.000105	0.00033	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—TYK2—Crohn's disease	0.000103	0.000325	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—CXCL8—Crohn's disease	9.88e-05	0.000311	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—JAK2—Crohn's disease	9.83e-05	0.00031	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CXCL8—Crohn's disease	9.82e-05	0.00031	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SMAD3—Crohn's disease	9.33e-05	0.000294	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—FADS1—Crohn's disease	9.02e-05	0.000284	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CXCL8—Crohn's disease	8.97e-05	0.000283	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CXCL8—Crohn's disease	8.76e-05	0.000276	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL2RA—Crohn's disease	8.64e-05	0.000272	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—FADS1—Crohn's disease	8.5e-05	0.000268	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GPX4—Crohn's disease	8.45e-05	0.000266	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	8.39e-05	0.000264	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	8.25e-05	0.00026	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GCKR—Crohn's disease	8.16e-05	0.000257	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GPX4—Crohn's disease	7.96e-05	0.000251	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TYK2—Crohn's disease	7.88e-05	0.000248	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GCKR—Crohn's disease	7.69e-05	0.000242	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—JAK2—Crohn's disease	7.52e-05	0.000237	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MTMR3—Crohn's disease	7.14e-05	0.000225	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CXCL8—Crohn's disease	6.86e-05	0.000216	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL6—Crohn's disease	6.53e-05	0.000206	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TYK2—Crohn's disease	6.09e-05	0.000192	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ALB—Crohn's disease	5.97e-05	0.000188	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JAK2—Crohn's disease	5.81e-05	0.000183	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—FADS1—Crohn's disease	5.56e-05	0.000175	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	5.54e-05	0.000175	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—STAT3—Crohn's disease	5.52e-05	0.000174	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ALB—Crohn's disease	5.48e-05	0.000173	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ALB—Crohn's disease	5.32e-05	0.000168	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCL8—Crohn's disease	5.3e-05	0.000167	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS2—Crohn's disease	5.22e-05	0.000165	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GPX4—Crohn's disease	5.21e-05	0.000164	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL6—Crohn's disease	5.04e-05	0.000159	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GCKR—Crohn's disease	5.03e-05	0.000158	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS2—Crohn's disease	4.8e-05	0.000151	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS2—Crohn's disease	4.66e-05	0.000147	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—STAT3—Crohn's disease	4.26e-05	0.000134	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL6—Crohn's disease	3.86e-05	0.000122	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL6—Crohn's disease	2.98e-05	9.38e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALB—Crohn's disease	2.6e-05	8.18e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALB—Crohn's disease	2.45e-05	7.71e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS2—Crohn's disease	2.27e-05	7.16e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS2—Crohn's disease	2.14e-05	6.75e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALB—Crohn's disease	1.6e-05	5.04e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS2—Crohn's disease	1.4e-05	4.41e-05	CbGpPWpGaD
